Tagged with Investment

Norway Karita Bekkemellem of Norwegian pharma association LMI highlights her work building up the profile of the industry in Norway, the market access and pricing challenges facing her member companies, and the country’s enduring potential as a leading clinical trial destination.   Through diligent and long-term thinking, and building bridges and…

Switzerland scienceindustries’ Stephan Mumenthaler outlines the business-friendly regulation necessary to maintain Swiss life sciences’ competitive edge, how the country’s evolving relationship with the EU stands to impact the industry, and Switzerland’s progress on the road to full digitalisation and Pharma 2.0   What our members want is a good and stable…

Switzerland Interpharma CEO Dr René P Buholzer outlines the holistic strategy that needs to be put in place to maintain Switzerland’s leading position in innovation, market access and reimbursement challenges for new medicines, and why an open, globalised Europe is key for security of supply.   The challenge for the future…

Japan Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park, gives an insider’s take on the opportunities and challenges for pharma companies in the large, innovation-friendly, but often misunderstood, Japanese market.   Japan is the world’s third-largest economy and second-largest pharmaceutical and medtech market, and yet it still holds a…

China A roundup of latest news from Chinese pharma and biotech, including a record high share price for Hansoh, strategic healthcare partnerships, venture capital gains, and recent IPO news from Sunshine Guojian and Tigermed.   China’s Hansoh Pharma out-licenses cancer drug to U.S. start-up EQRx https://www1.hkexnews.hk/listedco/listconews/sehk/2020/0723/2020072300084.pdf Hansoh Pharmaceutical Group led by…

Boehringer Ingelheim With its brand new hub in Shanghai dedicated to research, business development and venture funding, German pharma giant Boehringer Ingelheim is taking a step further toward accessing innovation from the Chinese biotech industry.   Boehringer Ingelheim has its sights set on establishing a deeper rapport with the Chinese biotech sector.…

Roundup A roundup of the latest from Chinese pharma and biotech, including Boehringer Ingelheim’s new Shanghai R&D hub, new HKEX IPO successes for Chinese firms, further progress for Clover’s COVID-19 vaccine candidate, and more.   Boehringer creates Shanghai hub to connect with Chinese R&D groups https://www.fiercebiotech.com/biotech/boehringer-creates-shanghai-hub-to-connect-chinese-r-d-groups With China’s domestic biotech scene…

France French pharma giant Sanofi is pivoting its focus to invest more heavily in vaccines with a plan to invest USD 679 million in vaccine manufacturing operations in the next two years. This announcement came shortly after news of further rounds of layoffs of research staff working on cardiovascular diseases and…

Algeria In Algeria, the supplementary Finance Law for 2020 has just been published in the Official Gazette. This law materializes the authorities’ will to significantly ease the control of foreign investments in order to boost Foreign Direct Investment (FDI) and to accelerate the diversification of the national economy.   Despite several…

Hong Kong Dr Desmond Hau, CEO of Pangenia Inc, sits down with PharmaBoardroom to shed light on the company’s progress since taking the reins three years ago. Hau also explains Pangenia’s strategy to develop their brand in South East Asia, the changes he foresees for the industry post the COVID-19 pandemic, and…

Hong Kong Michael Chan, Senior Vice President of Global Issuer Services for the Hong Kong Exchange (HKEX) highlights the vibrancy and diversity that biotechs have brought to the market, HKEX’s three unique advantages, and how the Hong Kong market aims to adapt to greater demands for diversity.    Hong Kong has a…

USA KV Kumar, head of the Indian American International Chamber of Commerce, gives an account of the bilateral trade relations between India and the US and candidly speaks about the opportunities for Indian generic companies in the world’s largest pharmaceutical market. He addresses the need for supply chain diversification in light…